Adams Thomas Edward 4

4 · KORU Medical Systems, Inc. · Filed Mar 18, 2026

AI-generated summary of this filing

Updated Mar 18, 2026

KORU Medical (KRMD) CFO Thomas Adams Exercises Options, Receives RSUs

What Happened

Thomas E. Adams, Chief Financial Officer of KORU Medical Systems (KRMD), reported exercising/converting a derivative to acquire 5,404 shares on March 16, 2026. On the same date 2,123 shares were withheld/disposed to satisfy tax obligations (reported value $9,086 at $4.28 per share). On March 17, 2026 he was granted three restricted stock unit (RSU) awards totaling 136,326 units (38,918 + 38,918 + 58,490), reported as acquisitions at $0.00 (derivative/award).

Key Details

Transaction dates/prices:
- 2026-03-16: Exercise/conversion of derivative — 5,404 shares acquired at $0.00 (M).
- 2026-03-16: Shares withheld to satisfy tax obligations — 2,123 shares disposed at $4.28 each, total $9,086 (F).
- 2026-03-17: Three RSU grants totaling 136,326 units (A), recorded at $0.00 (derivative awards).
Net immediate effect reported: +5,404 shares acquired, -2,123 shares withheld for taxes → net +3,281 shares added immediately; plus 136,326 RSUs granted (contingent).
Shares owned after the transaction: not specified in the filing.
Notable footnotes:
- F1/F3: Each RSU represents a contingent right to one share on vesting.
- F2: Shares were withheld to satisfy tax obligations upon vesting.
- F4: One RSU award vests in equal increments beginning March 17, 2027 (time-based).
- F5: One award vests based on performance through Dec 31, 2028 (payout 0%–150% of target; 100% on a change in control).
- Awards granted under the Issuer’s 2024 Omnibus Equity Incentive Plan.
Filing timeliness: no late filing flag shown in the summary provided.

Context

The March 16 action is an exercise/conversion of a derivative (reported as M). The 2,123-share disposition is tax withholding (code F), which is a routine administrative step and not an open-market sale.
The March 17 entries are RSU grants (not immediate open-market purchases)—these are contingent awards that vest per the stated schedules and performance conditions, so they do not represent immediately marketable common shares.
The filing includes a standard remark that the statement should not be construed as admission of beneficial ownership for Section 16 purposes.

Form 4

Period: 2026-03-16

Chief Financial Officer

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-03-16+5,404→ 5,404 total
Tax Payment
Common Stock
[F2]
2026-03-16$4.28/sh−2,123$9,086→ 3,281 total
Award
Restricted Stock Unit
[F3][F4]
2026-03-17+38,918→ 38,918 total
→ Common Stock (38,918 underlying)
Award
Performance Stock Unit
[F3][F5]
2026-03-17+38,918→ 38,918 total
→ Common Stock (38,918 underlying)
Award
Option to buy Common Stock
[F4]
2026-03-17+58,490→ 58,490 total
Exercise: $4.35Exp: 2036-03-17→ Common Stock (58,490 underlying)

Footnotes (5)

[F1]Represents common stock issued upon vesting of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock upon vesting.
[F2]Represents shares withheld to satisfy tax obligations upon vesting of restricted stock units.
[F3]Each unit represents a right to receive one share of common stock underlying the vested award on the applicable vesting date.
[F4]This restricted stock unit award was granted under the Issuer's 2024 Omnibus Equity Incentive Plan. The units comprising the award vest in equal increments on March 17, 2027 and each first, second and third anniversaries thereof (each, a vesting date).
[F5]These units will vest based upon the achievement of certain performance conditions as of December 31, 2028. The amount reported represents the amount of shares payable at target performance; the Reporting Person could earn 0%-150% of the amount reported depending on the level of performance achieved. These units will vest at 100% of the amount reported upon a change in control of the Company prior to December 31, 2028.

Signature

/s/ Thomas Edward Adams|2026-03-18

1 file